

Pressure BioSciences, Inc. (NASDAQ: PBIO)



Pressure BioSciences, Inc., a technology-driven life sciences company headquartered in South Easton, Massachusetts, is engaged in the research, development and commercialization of products based on pressure cycling technology (PCT). PCT is a unique platform technology that is revolutionizing the sample preparation process in biological research and other scientific analyses. PCT uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The Company, which began significant operations in 2005 and is a successor of Boston Biomedica, Inc. (also founded by Pressure BioSciences President & CEO Richard Schumacher) currently holds 13 U.S. and 6 foreign patents covering multiple PCT applications in the life sciences, including genomic and proteomic sample preparation, pathogen inactivation, the control of enzymatic and other chemical reactions, immunodiagnostics and protein purification. It sells and installs pressure generating instruments ("Barocyclers") with consumable accessories and reagent kits, and additionally generates revenues from instrument service contracts and replacement parts, as well as NIH and other grants. Its PCT-based products and applications are targeted for the mass spectrometry, enzymology, biomarker discovery, soil and plant biology, histology, forensics and counter-bioterror markets. The Company has already seen early market traction; current customers include researchers at more than 75 academic laboratories, government agencies, and biotechnology, pharmaceutical and other life sciences companies in the U.S. and abroad, such as Amgen, Novartis, Lilly, Pacific Northwest National Laboratory, NIH, FDA, FBI, USDA, Harvard, and NYU.

In February 2009, the Company completed a private placement of convertible preferred stock and warrants, resulting in gross proceeds of approximately \$1.8 million. Due to provisions in the 2009 Stimulus Act, the Company became eligible for an income tax refund in the amount of approximately \$623,000. Given its planned average quarterly cash burn of under \$600,000 in 2009, the Company appears to have sufficient capital to fund its operations through the second quarter of 2010 and hopes to reach profitability by the end of 2011.



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. Readers should understand target price is not a prediction or forecast, but merely reflects possible returns to prior historical levels based on improved market conditions and eventual realization of company milestones and is therefore highly speculative. The featured company paid a consulting fee of \$6,000 to Alan Stone & Company LLC for preparation and distribution of this profile and registration at the WallStreet Research Small Cap conference. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.

CURRENT PRICE: \$1.62
 52-WEEK RANGE: \$0.55 - \$3.75
 AVG DAILY VOLUME (90-DAY): 7,100
 FLOAT: 1.9 million
 OUTSTANDING SHARES: 2.2 million
 FULLY DILUTED SHARES: 3.8 million
MARKET CAPITALIZATION: \$3.6 million

INCOME STATEMENT HIGHLIGHTS

REVENUES: \$1.0 million
 REVENUE PER SHARE: \$0.47
 QTR REVENUE GROWTH: 132%
 GROSS PROFIT: \$451.3 thousand
 EBITDA: (\$4.2 million)
 NET INCOME: (\$3.8 million)
 DILUTED EPS: (\$1.73)

All figures for twelve months ended March 31, 2009

BALANCE SHEET HIGHLIGHTS

CASH & EQUIVALENTS: \$2.2 million
 WORKING CAPITAL: \$3.1 million
 TOTAL ASSETS: \$4.4 million
 LONG TERM DEBT: Nil
 NET WORTH: \$3.6 million

All figures as of March 31, 2009

RECENT COMPANY HEADLINES

Monday, June 1, 2009 — Pressure BioSciences CEO presides over The NASDAQ Stock Market Opening Bell ceremony in celebration of the release of the Company's next generation PCT-based sample preparation product, the PCT MicroTube Adapter Kit, which was launched at the 57th Annual Conference of the American Society for Mass Spectrometry taking place in Philadelphia, on June 1st-4th, to an extremely strong reception.

INDUSTRY STATISTICS

The Emmes Group in 2008 estimated that the market for biological sample preparation products is comprised of up to 80,000 laboratories and 500,000 researchers worldwide.

A report issued by Strategic Directions International, a provider of market intelligence, estimates that the global sample preparation market will reach \$6 billion in 2009.

CORPORATE CONTACT INFORMATION

Pressure BioSciences, Inc.
 Richard T. Schumacher, President & CEO
 14 Norfolk Avenue
 South Easton, MA 02375
 Phone: 508-230-1828
 Fax: 508-230-1829
 Web Site: www.pressurebiosciences.com
 Email: info@pressurebiosciences.com